Edition:
United States

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

67.30USD
3:26pm EDT
Change (% chg)

$0.20 (+0.30%)
Prev Close
$67.10
Open
$67.10
Day's High
$67.56
Day's Low
$66.95
Volume
1,426,931
Avg. Vol
2,945,986
52-wk High
$103.09
52-wk Low
$65.38

Latest Key Developments (Source: Significant Developments)

Gilead Sciences CEO John Milligan's 2016 total compensation was $13.9 mln- SEC Filing
Monday, 27 Mar 2017 05:36pm EDT 

Gilead Sciences Inc : Gilead Sciences Inc- CEO John F. Milligan's 2016 total compensation was $13.9 million- SEC Filing . Executive chairman John Martin's FY 2016 total compensation was $10.4 million . CFO Robin Washington's FY 2016 total compensation was $5.1 million versus $5.6 million in FY 2015 .Chief Scientific Officer Norbert Bischofberger's FY 2016 total compensation was $6.2 million versus $6.95 million in FY 2015.  Full Article

Gilead Sciences lists EPCLUSA on public drug plan to treat chronic hepatitis C infection
Tuesday, 21 Mar 2017 04:00pm EDT 

Gilead Sciences Inc - :British Columbia lists EPCLUSA on public drug plan to treat all six genotypes of chronic hepatitis C infection.  Full Article

Gilead Sciences says EPCLUSA added to Liste des médicaments de la RAMQ
Monday, 20 Mar 2017 12:25pm EDT 

Gilead Sciences Inc :EPCLUSA, to treat all six genotypes of chronic Hepatitis C infection, added to Liste des médicaments de la RAMQ.  Full Article

Galapagos announces two Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease
Friday, 10 Mar 2017 01:30am EST 

Galapagos Nv : announces two new phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease .studies are being led by filgotinib collaboration partner Gilead Sciences.  Full Article

Gilead Sciences Canada says Ontario to list Epclusa on public drug plan to treat all six genotypes of chronic Hepatitis C infection
Wednesday, 22 Feb 2017 11:36am EST 

Gilead Sciences Canada :Gilead Sciences Canada- effective feb 28, ontario to list epclusa on public drug plan to treat all six genotypes of chronic hepatitis c infection.  Full Article

Gilead receives approval in Canada for Odefsey for treatment of HIV-1 infection
Thursday, 16 Feb 2017 11:30am EST 

Gilead Sciences Inc :Gilead receives approval in Canada for Odefsey for the treatment of HIV-1 infection.  Full Article

AMYGDALA NEUROSCIENCES ACQUIRES GS-6637 FROM GILEAD SCIENCES
Thursday, 16 Feb 2017 10:03am EST 

Amygdala Neurosciences: AMYGDALA NEUROSCIENCES ACQUIRES GS-6637 FROM GILEAD SCIENCES .AMYGDALA NEUROSCIENCES SAYS "IN 2017, LOOK FORWARD TO INITIATING CLINICAL TRIALS FOR TREATMENT OF BOTH COCAINE AND ALCOHOL USE DISORDERS" FOR GS-6637.  Full Article

Gilead Sciences sets quarterly dividend of $0.52 per share
Tuesday, 7 Feb 2017 04:02pm EST 

Gilead Sciences Inc : Sets quarterly dividend of $0.52 per share .Increases quarterly dividend by 10 percent.  Full Article

Gilead Sciences reports Q4 earnings per share $2.34
Tuesday, 7 Feb 2017 04:01pm EST 

Gilead Sciences Inc : Gilead Sciences announces fourth quarter and full year 2016 financial results . Q4 non-GAAP earnings per share $2.70 excluding items . Q4 earnings per share $2.34 . Q4 revenue $7.3 billion versus I/B/E/S view $7.15 billion . Q4 earnings per share view $2.61 -- Thomson Reuters I/B/E/S . Gilead Sciences Inc qtrly harvoni sales $1,640 million versus $3,345 million . Gilead Sciences Inc qtrly sovaldi sales $541 million versus $1,547 million . Gilead Sciences Inc sees full year 2017 net product sales $22.5 billion - $24.5 billion . Gilead Sciences Inc sees full year 2017 net product sales $22,500 - $24,500 million . Gilead Sciences sees 2017 diluted EPS impact of acquisition-related,up-front collaboration, stock-based compensation and other expenses $0.84 -$0.91 .Gilead Sciences Inc sees 2017 non gaap product gross margin 86% - 88%.  Full Article

Gilead COO says slowdown in patients starting hep C therapies to continue in 2017
Monday, 9 Jan 2017 02:40pm EST 

Gilead Sciences Inc : Gilead exec says slowdown in patients starting hepatitis c therapies to continue in 2017 . Gilead exec says hep c sales slowdown most apparent in Japan, southern Europe and United States - JP Morgan healthcare conference . Gilead COO Kevin Young says not sure when hepatitis c sales decline will bottom out Further company coverage: [GILD.O] (Reporting By Caroline Humer) ((caroline.humer@thomsonreuters.com;)).  Full Article

More From Around the Web

BRIEF-Gilead Sciences CEO John Milligan's 2016 total compensation was $13.9 mln- SEC Filing

* Gilead Sciences Inc- CEO John F. Milligan's 2016 total compensation was $13.9 million- SEC Filing